Treatment of SLE and Secondary Sjogren’s syndrome with Belimumab
Treatment of SLE and Secondary Sjogren’s syndrome with Belimumab
Journal of Immunobiology (Hilaris Publishing S.L) has announced almost 50% discount on article processing charge to commemorate its 10th Anniversary.
Journal of Immunobiology is an open access, peer-reviewed journal that focuses and welcomes submissions on all aspects of Immunobiology, Immunology, Autoimmunity, Innate Immunity, Adaptive Immunity, immunization, Immunogenetics, Immune Disorders, Immunodeficiency, Immune inflammation, Immunoinformatics, Clinical Immunology, Allergy & Immunology, Clinical & Vaccine Immunology, Inflammatory Disorders, Autoimmune Disorders, Immunotherapy and Immunopathology of infectious, allergic and autoimmune disease etc.
It gives us great pleasure to announce the call for paper on the occasion of 10th Anniversary of the Journal at special and hefty discount of up to 50 % on one-time article processing charge. Prospective academicians and scientists are encouraged to utilize this opportunity to get their articles reviewed, processed and published at relatively faster pace and at lower charges. In addition to this, the authors who publish with us during the year-long celebrations will also be eligible for academic awards recommended by the editorial panel.
The Archive page contains wide variety of articles such as Research / Review / Case reports / short communication / Mini review / Prospective / Letter to Editors Etc. We would like introduce a Short Communication which has been spread to the widest audience of experts; and thus increased in readership, citations and altimetry score.
Title: “Treatment of SLE and Secondary Sjogren’s Syndrome with Belimumab”
Abstract: Belimumab neutralizes the soluble form of B-cell activating factor and is FDA-approved for treating Systemic Lupus Erythematosus (SLE). In this retrospective analysis 16 female SLE patients had been treated with belimumab according to FDA guidelines along with any immunosuppressive drugs or antimalarial drugs they had previously been prescribed, in addition to prednisone. Thirteen of 16 patients presented with serologic evidence of positive antinuclear antibody titer while several other SLE patients also had clinical evidence of secondary Sjogren ’s syndrome (2°SS), the latter supported by sicca symptoms and positive anti-Sjogren’s-syndrome-related antigen A antibody titer. Changes in the SLE symptoms after belimumab therapy was assessed by the recipient’s responses on the Short Form-36 questionnaire. Ten of the 16 SLE patients reported a decrease in arthralgias or in symptoms of arthritis while fatigue was reduced in 9/16 patients. However, SLE patients with sicca symptoms failed to show any change in the Short Form-36 score after treatment with belimumab. In conclusion, although the results in this small cohort study supported the use of belimumab as an adjunctive therapy for SLE, sicca symptoms associated with 2°SS did not appear to respond to belimumab.
To have a glance at the full length manuscript, you can visit us at our archive page and Currently, Journal’s Archive is holding not only normal issues but also focusing on special issues. The purpose of special issues is to publish the most exciting research with respect to the subjects of Immunology / Immunobiology and to provide a rapid turn-around time regarding reviewing and publishing, and to publicize the articles freely for research, teaching and reference purposes. Submit manuscript of your research articles or special issue articles online through manuscript submission or forwarded to the Editorial Office at immunobio@immunologyjournals.org
Media Person,
David Williams
Journal Coordinator
Journal of Immunobiology